Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-free: Booster-free ART in HIV
NCT06037564Phase 4Enrolling by invitation
- Sponsor
- Insel Gruppe
- Start
- Nov 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doravirine, dolutegravir and lamivudine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Loss of viral suppression at 48 weeks. Started Nov 2023; status: enrolling by invitation.
02
Drugs
doravirinedolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06037564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037564.